Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
PALI
PALI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PALI News
Wall Street Analysts Adjust Ratings
Feb 25 2026
Benzinga
Palisade Bio to Participate in Immunology Symposium
Feb 09 2026
Newsfilter
Palisade Bio's PALI-2108 Clinical Data Selected for Two International IBD Meetings
Jan 16 2026
Globenewswire
Palisade Bio Secures $500K Investment to Advance PALI-2108
Jan 07 2026
Globenewswire
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
Jan 05 2026
Benzinga
Palisade Bio Secures Japanese Patent for PALI-2108, Phase 2 Trials Planned for 2026
Dec 30 2025
Globenewswire
Palisade Bio Secures Japanese Patent for PALI-2108, IND Submission Planned for 2026
Dec 30 2025
Newsfilter
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
Dec 29 2025
Benzinga
DigitalBridge Group Inc Acquired by SoftBank Group for Approximately $4 Billion
Dec 29 2025
Benzinga
Bolt Projects Raises FY2026 Sales Guidance to $11 Million
Dec 29 2025
Benzinga
Palisade Bio (PALI) Receives Upgrade to Buy: Key Information You Need to Know
Dec 19 2025
NASDAQ.COM
Tilray Brands, SuperX AI Technology, and Other Major Stocks Decline in Friday's Pre-Market Trading
Nov 28 2025
Benzinga
Hyundai unveils new rugged concept SUV to highlight off-road aspirations
Nov 20 2025
CNBC
Palisade Bio Names Sharon Skare as Vice President and Global Head of Clinical Operations
Oct 28 2025
Newsfilter
Palisade Bio Begins Dosing First Patients in Phase 1b Trial of PALI-2108, an Oral First-In-Class PDE4 Inhibitor Prodrug for Fibrostenotic Crohn's Disease Treatment
Oct 20 2025
Newsfilter
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI)
Oct 20 2025
PRnewswire
Show More News
